NCT05745506Not yet recruiting
Effect of Sleep Disorder on the Development of Lung Tumors
Effect of Sleep Disorder on the Development of Lung Tumors, a Perspective, Single-centered Study
Source: ClinicalTrials.gov · Last updated 27 Feb 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to observe the lung tumor development in lung tumor patients with long-term sleep disorder. The main questions it aims to answer are: * will long-term sleep disorder promote the malignancy of lung tumor * if so, how exactly will the microenvironment of lung tumor change Participants will receive PSQI scale and MRI functional brain imaging before surgery, blood and tumor tissue will be collected during the surgery. Researchers will set non-sleep disorder group as control group to see if lung tumor microenvironment change when long-term sleep disorder exists in lung tumor patiens.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 16 Feb 2023
- Start date
- Feb 2023
- Primary completion date
- Jun 2026
- Lead sponsor
- RenJi Hospital
- Diseases
- Lung cancer
- NCT number
- NCT05745506
What you commit to
- Study type: Observational
- Planned participants: 200
- From Feb 2023 to the primary completion date, Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with preoperative neoadjuvant radiotherapy
Other illness
- Combination of serious heart, liver, kidney, central nervous system, blood system, immune system diseases or serious mental illness
- Combination of other cancers
- untreated active lung infection
Who the study is looking for
- 18-75 years old
- elective sublobectomy for primary lung tumor
- ASA grade I-II
- Informed consent of the patient or family
Age in the registry: 18 years to 75 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.